Combination Treatment Using Capravirine (AG1549), Nelfinavir, and Two Nucleoside Reverse Transcriptase Inhibitors in HIV Patients Who Failed Initial Combination Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

January 31, 2000

Conditions
HIV Infections
Interventions
DRUG

Capravirine

DRUG

Nelfinavir mesylate

Trial Locations (34)

10014

Liberty Medical, New York

10029

Mount Sinai Med Ctr, New York

11030

North Shore Univ Hosp, Manhasset

11432

Biomedical Research Alliance of New York, Jamaica

22203

Infectious Disease Physicians Inc, Annandale

30308

AIDS Research Consortium of Atlanta, Atlanta

30309

Braude Mermin Spivey MD PC, Atlanta

32805

Orange County Health Dept, Orlando

32960

Treasure Coast Infectious Disease Consultants, Vero Beach

33139

South Shore Hosp, Miami

Immunity Care and Research Inc, Miami Beach

33306

Community Health Care, Fort Lauderdale

33308

Therafirst Med Ctr, Fort Lauderdale

33602

Hillsborough County Health Dept, Tampa

33765

Clin Research of West Florida, Clearwater

33881

Polk County Health Dept, Winter Haven

34205

Bach and Godofsky, Bradenton

34239

Infectious Diseases Associates, Sarasota

77555

Univ TX Galveston Med Branch, Galveston

78705

Central Texas Clinical Research, Austin

80262

Univ of Colorado Health Sciences Ctr, Denver

85016

Phoenix Body Positive, Phoenix

90211

Pacific Oaks Med Group, Beverly Hills

90502

Harbor - UCLA Med Ctr, Torrance

92101

Apogee Med Group, San Diego

92262

First Choice Medical, Palm Springs

94109

Saint Francis Mem Hosp / HIV Care Unit, San Francisco

94118

Kaiser Foundation Hospital, San Francisco

02114

Massachusetts Gen Hosp, Boston

02115

Fenway Community Health Ctr, Boston

07018

VAMC New Jersey Healthcare System, East Orange

07753

Jersey Shore Med Ctr, Neptune City

08876

Infectious Disease Assoc of Central Jersey, Somerville

009091711

Clinical Research Puerto Rico Inc, San Juan

Sponsors
All Listed Sponsors
lead

Agouron Pharmaceuticals

INDUSTRY

NCT00004985 - Combination Treatment Using Capravirine (AG1549), Nelfinavir, and Two Nucleoside Reverse Transcriptase Inhibitors in HIV Patients Who Failed Initial Combination Therapy | Biotech Hunter | Biotech Hunter